Tech Company Financing Transactions
Neumentum Funding Round
Neumentum, operating out of Morristown, received $6 million from Brookline Capital Markets.
Transaction Overview
Company Name
Announced On
12/7/2017
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Series A
Investors
Proceeds Purpose
The funding will be used to advance a pipeline of non-opioid drug candidates that have the potential to treat pain, without the risks of abuse, misuse and diversion frequently associated with opioids. Lead non-opioid product candidates NTM-001 (pre-mixed bag ketorolac continuous infusion) and NTM-002 (IV patient-controlled analgesia) have the potential to deliver opioid-strength analgesia, which may reduce the need for opioids in clinical settings.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
39 Eagle Nest Rd.
Morristown, NJ 07960
USA
Morristown, NJ 07960
USA
Phone
Website
Email Address
Not Recorded
Overview
Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company. More than 100 million Americans suffer from pain and many patients experiencing moderate to severe pain receive prescription opioids. Treatment with opioids comes with inherent risks.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Scott Shively
Chief Medical Officer
Ilona Steigerwald
Chief Scientific Officer
Robert Raffa
VP - Bus. Development
Sarah Faust
Browse more venture capital transactions:
Prev: 12/7/2017: Maxwell Financial Labs venture capital transaction
Next: 12/7/2017: Obsidian Therapeutics venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record every notable VC transaction. VC transactions reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs